Analysis of Human ALS Tissues and Registry of ALS Patients

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Illinois at Chicago
Study ID
NCT05067179
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Study Details

Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain. This devastating disorder afflicts people in the prime of their lives. At the present time, there are no cures for this disorder, and current treatments are marginal at best. Despite years of intensive research, a fundamental understanding of this disease is still lacking. There is a need to identify both reliable markers of disease progression and effective treatments. The goal of this research is to bring a greater understanding of ALS patients closer to the research studies that can lead to new hypotheses and approaches.

Key Dates

Start date
Sep 1, 2020
Status verified
May 2025
Primary completion
Jan 1, 2030
Completion
Jan 1, 2030

Study Design

Enrollment
40 participants (estimated)

Primary Outcome Measure

Imaging biomarkers [ Time Frame: Within 6 months of participant enrollment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Illinois at ChicagoChicagoIllinois60612
Ayo Fasawe, RN, MS
[email protected]
312-413-7908
Charles Abrams, MD, PhD (SUB_INVESTIGATOR)
Diana Mnatsakanova, MD (SUB_INVESTIGATOR)
Girouard Michelle, MD (SUB_INVESTIGATOR)

Find similar trials in Chicago, IL

By research site
University of Illinois at Chicago· Chicago, IL

Related Studies